Solomon Moshkevich Sells 293 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 293 shares of Natera stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $235.00, for a total value of $68,855.00. Following the transaction, the insider owned 144,699 shares of the company’s stock, valued at $34,004,265. This trade represents a 0.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The shares were sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The stock was sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $193,858.56.

Natera Trading Up 0.1%

Shares of NTRA traded up $0.13 during trading hours on Thursday, reaching $242.91. 971,052 shares of the stock traded hands, compared to its average volume of 950,311. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The stock has a fifty day simple moving average of $233.44 and a 200 day simple moving average of $190.60. The company has a market cap of $33.60 billion, a price-to-earnings ratio of -106.07 and a beta of 1.62.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. During the same quarter last year, the business posted ($0.26) EPS. The company’s quarterly revenue was up 34.7% on a year-over-year basis. Analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTRA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their price objective on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Citigroup assumed coverage on shares of Natera in a report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price target on the stock. Piper Sandler increased their price target on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Stephens raised their price objective on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Guggenheim boosted their target price on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.50.

Hedge Funds Weigh In On Natera

Several hedge funds have recently made changes to their positions in NTRA. Rakuten Investment Management Inc. bought a new stake in Natera during the 3rd quarter worth approximately $34,096,000. SWS Partners grew its position in shares of Natera by 11.8% during the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after purchasing an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. increased its holdings in shares of Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after purchasing an additional 5,614 shares during the period. Baird Financial Group Inc. raised its position in shares of Natera by 277.8% in the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after buying an additional 19,576 shares in the last quarter. Finally, Orion Porfolio Solutions LLC boosted its stake in Natera by 68.8% during the second quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock valued at $2,051,000 after buying an additional 4,946 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.